Thrombophilia in coronary artery disease: A double jeopardy

Indian Journal of Medical Research

Volumn 120, Issue 1, 2004, Pages 13-23

  Mohanty, D ^a   Ghosh, K ^a   Khare, A ^a   Kulkarni, B ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

Coronary artery disease; Factor V Leiden; Fibrinogen polymorphisms; Homocysteine; Platelet alloantigens; Protein C pathway

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CLOPIDOGREL; COAGULATING AGENT; EPTIFIBATIDE; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; HOMOCYSTEINE; LIPOPROTEIN; LIPOPROTEIN A; PROSTAGLANDIN SYNTHASE; PROTEIN C; PROTEIN S; PROTHROMBIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBOCYTE ANTIGEN; TICLOPIDINE; UNINDEXED DRUG; VON WILLEBRAND FACTOR; WARFARIN; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; AGE; AGRANULOCYTOSIS; ANGINA PECTORIS; ARTERY THROMBOSIS; ATHEROMA; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; DRUG MECHANISM; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; HEMOSTASIS; HEREDITY; HUMAN; INCIDENCE; INDIA; LABORATORY TEST; MEDICAL RESEARCH; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; CORONARY ARTERY ATHEROSCLEROSIS; HEART INFARCTION; METABOLISM;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; HUMANS; INDIA; MYOCARDIAL INFARCTION; THROMBOPHILIA;

EID: 4344649638     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Middeldrop S, Buller HR, Prins MH, Hirsh J. Approach to the thrombophilia patient. Hemostasis and Thrombosis. Basic Principles and Clinical Research, 4th ed. PA, USA: Lippincott Williams and Wilkins; 1085-1100.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
4. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
5. Tybjaerg-Hansen A, Agerholm-Larsen B, Humpries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G455-A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen but not ischaemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997; 99: 3034-9.
6. Curran JM, Evans A, Arveiier D, Luc G, Ruidavets JB, Humphries SE, et al. The α-fibrinogen T/A 312 polymorphism in the ECTIM study. Thromb Hemost 1998; 79: 1057-8.
7. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
9. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
10. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
11. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79: 912-5.
12. Gardemann A, Arsic T, Katz N, Tilmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 1999; 81: 208-13.
13. Townend J, O'Sullivan J, Wilde JT. Hyperhomocysteinaemia and vascular disease. Blood Rev 1998; 12: 23-34.
14. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-13.
15. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
16. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results form the Third National Health and Nutrition Examination Survey. Am Heart J 2000; 139: 446-53.
17. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26: 795-800.
18. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
19. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160: 422-34.
20. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
21. Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with an increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997; 30: 1206-11.
22. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-72.
23. Szczeklik A, Sanak M, Jankowski M, Dropinski J, Czachor R, Musial J, et al. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 2001; 101: 36-9.
24. Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, Marz W, et al. Polymorphism of platelet membrane glycoprotein IIIa: human splatelet antigen 1b (HPA-1b/P1A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998; 79: 731-5.
25. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagaliabue L, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
26. Herrmann SM, Poirier O, Marques-Vidal P, Evans A, Arveiler D, Luc G, et al. The Leu33/Pro polymorphism (P1A1/P1A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thromb Haemost 1997; 77: 1179-81.
27. Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewiez PM, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999; 353: 708-12.
28. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GPIIIa P1 (A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-8.
29. A2): no association with platelet fibrinogen binding. Br J Haematol 1999; 105: 664-6.
30. Hato T, Minamoto Y, Fukuyama T, Fujita S. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 1997; 80: 1222-4.
31. Bottiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schomig K, et al. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000; 83: 559-62.
32. Moshfegh K, Wuillemin WA, Redendo M, Lammle B, Beer JH, Liechti-Gallati S, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with the risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-4.
33. Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ, et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106: 771-6.
34. Frank MB, Reiner AP, Schwartz SM, Kumar PN, Pearce RM, Argogast PG, et al. The Kozak sequence polymorphism of platelet glycoprotein Ibα and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood 2001; 97: 875-9.
35. Douglas H, Michaelides K, Gorog DA, Durante-Mangoni E, Ahmed N, Davies GJ, et al. Platelet membrane glycoprotein Ibα gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart 2002; 87: 70-4.
36. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
37. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
38. Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998; 80: 878-80.
39. Gambhir JK, Kaur H, Gambhir DS, Prabhu KM. Lipoprotein (a) as an independent risk factor for CAD in patients below 40 years of age. Indian Heart J 2000; 52: 411-5.
40. Gupta R, Vashisht S, Bahl VK, Wasir HS. Correlation of lipoprotein (a) to angiographically defined coronary artery disease in Indians. Int J Cardiol 1996; 57: 265-70.
41. Isser HS, Puri VK, Narain VS, Saran RK, Dwivedi SK, Singh S. Lipoprotein (a) and lipid levels in young patients with myocardial infarction and their first degree relatives. Indian Heart J 2001; 53: 463-6.
42. Ridker PM, Vaughan DE, Stampfer MJ, Manson J, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
43. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardia infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
44. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von-willebrand factor are significant risk factors for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-23.
45. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, et al. Tissue plasminogen activator and the risk of myocardial infarction. The Rotterdam study. Circulation 1997; 95: 2623-7.
46. Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vanghan DE. Alu-repeat polymorphism in the gene coding for tissue type plasminogen activator (1-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 1687-90.
47. Steeds R, Adams M, Smith P, Channer K, Samani NJ. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost 1998; 79: 980-4.
48. Margaglione M, Di Minno G, Grandone E, Vecchione G, Glentano E, Cappucci G, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14: 1741-5.
49. Eriksson P, Kallin B, van't Hoft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
50. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen-activator inhibitor 1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999; 34: 1778-83.
51. Coller BS, Owen J, Jesty J, Horowitz D, Reitman MJ, Spear J, et al. Deficiency of plasma protein S, protein C or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7: 456-62.
52. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
53. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. FactorVIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999; 105: 110-6.
54. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and the incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
55. Iacoviello L, Di Castelnuovo A, De Knijiff P, D'Orazio A, Amore C, Arboretti R, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
56. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
57. Corral J, Gonzalez-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V. The F XIII Va134Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-7.
58. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
59. Enas EA, Dhawan J, Petkar S. Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein (a). Indian Heart J 1997; 49: 25-34.
60. Gupta R, Gupta VP. Meta-analysis of coronary heart disease prevalence in India. Indian Heart J 1996; 48: 241-5.
61. Mohan V, Deepa R, Rani SS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. The Chennai Urban Population Study (CUPS No.5). J Am Coll Cardiol 2001; 38: 682-7.
62. Reddy KS. Neglecting cardiovascular disease is unaffordable. Bull World Health Organ 2001: 79: 984-5.
63. Reddy KS. Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public Health Nutr 2002; 51: 231-7.
64. Govindaraju V, Neelam, Manjunath CN, Sundar KK. Lipoprotein (a) in coronary artery disease in Indian population. J Indian Med Assoc 2003; 101: 458-60.
65. Ganapathyraman L, Shanti P, Baba Krishnan K, Madhavan M, Lakshminathan C. Protein C levels in ischaemic heart disease. Indian Heart J 1996; 48: 125-7.
66. Jose J, Selvakumar D, Selvakumar R, Kanagasabapathy AS, Jeyaseelan L. Plasma fibrinogen-an independent risk factor for ischaemic heart disease. Indian Heart J 1998; 50: 45-8.
67. Gheye S, Lakshmi AV, Krishna TP, Krishnaswamy K. Fibrinogen and homocysteine levels in coronary artery disease. Indian Heart J 1999; 51: 499-502.
68. Deepa R, Velmurugan K, Saravanan G, Dwarakanath V, Agarwal S, Mohan V. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in south Indian male subjects. J Assoc Physicians India 2002; 50: 901-6.
69. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000; 355: 523-7.
70. Chacko KA. Plasma homocysteine levels in patients with coronary heart disease. Indian Heart J 1998; 50: 295-9.
71. Deepa R, Velmurugan K, Saravanan G, Karkuzhali K, Dwarkanath V, Mohan V. Absence of association between serum homocysteine levels and coronary artery disease in south Indian males. Indian Heart J 2001; 53: 44-7.
72. Sastry BK, Indira N, Anand B, Kedarnath, Prabha BS, Raju BS. A case-control study of plasma homocysteine levels in south Indians with and without coronary artery disease. Indian Heart J 2001; 53: 749-53.
73. Nair KG, Nair SR, Ashavaid TF, Dalal JJ, Eghlim FF. Methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia as a risk factor for coronary heart disease in the Indian population. J Assoc Physicians India 2002; 50 (Suppl): 9-15.
74. Puri A, Gupta OK, Dwivedi RN, Bharadwaj RPS, Narain VS, Singh S. Homocysteine and lipid levels in young patients with coronary artery disease. J Assoc Physicians India 2003; 51: 681-5.
75. Ghosh K, Shetty S, Madkaikar M, Pawar A, Nair S, Khare A, et al. Venous thromboembolism in young patients from western India: a study. Clin Appl Thromb Hemost 2001; 7: 158-65.
76. Herrmann FH, Salazar-Sanchez L, Schroder W, Grimm R, Schuster G, Jimenez-Arce G, et al. Prevalence of molecular risk factors FV Leiden, FVHR2, FII 20210 G>A and MTHFR 677CT in different populations and ethnic groups of Germany, Costa Rica and India. Int J Hum Genet 2001; 1: 33-9.
77. Mohanty D, Shetty S, Anil CR, Pathare A, Ghosh K, Yeolekar ME. Factor V Leiden gene mutation in young Indian patients with myocardial infarction. Curr Sci 1998; 74: 1078-80.
78. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
79. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 investigators. Circulation 1999; 99: 2720-32.
80. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 (Suppl 3): 5-16.
81. Low molecular weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease, (FRISC) Study Group. Lancet 1996; 347: 561-8.
82. Antman EM. Hirudin in acute myocardial infarction thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
83. Awidi A, Shannak M, Bseiso A, Kailani MA, Kailani MA, Omar N, et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999; 81: 582-4.
84. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-6.
85. Yu HH, Jourbran R, Asmi M, Law T, Spencer A, Jouma M, et al. Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls. Clin Chem 2000; 46: 258-64.